Overview
Yellow fever is a potentially severe viral infection transmitted by Aedes and Haemogogus mosquitoes. The yellow fever virus is a flavivirus in the same family as dengue, zika, and West Nile virus. Unlike some other viral infections, there is no specific treatment , management is entirely supportive. However, yellow fever is unique among febrile illnesses because it is vaccine-preventable, and vaccination is the most effective prevention strategy.
The disease has three epidemiological cycles: the urban cycle where Aedes mosquitoes transmit the virus between humans in urban areas, the intermediate cycle in forested areas where both humans and primates can be infected, and the sylvatic (wild) cycle maintained primarily in non-human primates with only occasional human cases.
Yellow fever was historically endemic in Ghana and West Africa and was responsible for significant mortality in coastal urban areas during the 18th and 19th centuries. While cases have become rare in Ghana in recent decades due to vaccination campaigns and vector control, the disease remains a public health threat. Sporadic cases continue to occur across sub-Saharan Africa, and outbreaks still develop in areas where vaccination coverage is inadequate. Travel-related cases in Ghana continue to occur when unvaccinated travelers arrive from endemic areas.
The incubation period ranges from three to six days, with most cases presenting three to four days after infection. Yellow fever presents clinically in two phases: an initial febrile phase lasting three to four days, followed by either recovery or progression to a toxic phase in approximately 15 percent of symptomatic cases. The toxic phase is characterized by multi-organ failure including hepatic failure, renal failure, and hemorrhage , and carries a case fatality rate of 50 to 85 percent even with intensive supportive care.
The name “yellow fever” derives from jaundice, the yellowing of skin and eyes that occurs in severe cases as a result of hepatic dysfunction.
Key Fact
Important
AT A GLANCE
Disease Summary
Symptoms
Febrile Phase Symptoms (Initial Phase)
The initial febrile phase lasts three to four days. Symptoms are initially non-specific and resemble other febrile illnesses.
Sudden High Fever
Severe Headache
Muscle and Joint Pain
Backache
Nausea and Vomiting
Facial Flushing and Conjunctival Injection
Remission Period
Some patients experience an apparent recovery during which fever temporarily resolves, usually lasting a few hours to a day. This deceptive improvement precedes the toxic phase.
Brief Apparent Recovery
Toxic Phase Symptoms (Second Phase)
These symptoms indicate progression to severe yellow fever. Seek urgent medical attention immediately if any of these develop.
Jaundice
Vomiting Blood
Black Tarry Stools
Decreased Urination
Confusion or Altered Mental State
Spontaneous Bleeding
Diagnosis
Clinical Assessment
Physical Examination
Laboratory Confirmation
Laboratory Tests
IgM Antibodies
IgM antibodies appear around day three to five of illness and peak during the first two weeks. The presence of IgM indicates acute or recent yellow fever infection. This is the most commonly available test for yellow fever diagnosis in many laboratories including those in Ghana. IgM testing is most useful from day three of illness onward.
PCR (Polymerase Chain Reaction)
PCR can detect yellow fever virus RNA in blood and is highly sensitive and specific, particularly during the first three to five days of illness before antibodies appear. A positive PCR confirms yellow fever infection. However, PCR is not widely available in most Ghanaian health facilities and is typically performed only in reference laboratories.
Viral Culture
Viral culture can grow yellow fever virus from blood samples taken during the first three to five days of illness when viremia (virus in the bloodstream) is highest. A positive culture confirms yellow fever infection but requires specialized laboratory facilities and is not routinely available.
IgG Antibodies
IgG antibodies appear around day seven of illness and persist for life, providing lifelong immunity. IgG alone indicates past infection and provides immunity against future infection. The presence of both IgM and IgG indicates acute or recent infection.
Complete Blood Count (FBC)
The complete blood count may reveal thrombocytopenia (low platelet count), leucopenia (low white blood cell count), and evidence of hemolysis. In severe yellow fever, rapidly falling platelet counts and prolonged prothrombin time indicate severe coagulopathy.
Liver Function Tests
Elevated liver enzymes (ALT, AST) and bilirubin indicate hepatic involvement. In severe yellow fever, very high bilirubin levels, prolonged prothrombin time, and low albumin indicate severe hepatic dysfunction.
Laboratory Note
The best diagnostic test depends on when in the illness the patient presents. In the first three to five days, PCR or viral culture are most useful. From day three onward, IgM serology becomes useful. The combination of clinical presentation, epidemiological history (travel to endemic area, lack of vaccination), and appropriate laboratory testing confirms yellow fever diagnosis.
Treatment
Supportive Care
There is no specific antiviral treatment that kills the yellow fever virus. Treatment is entirely supportive and focuses on maintaining organ function while the immune system clears the infection. This includes maintaining hydration, monitoring for complications, and managing fever and pain.
Fever and Pain Management
Paracetamol (acetaminophen) is used to manage fever and pain. Aspirin and non-steroidal anti-inflammatory drugs are avoided because they increase bleeding risk in yellow fever, particularly if coagulopathy develops.
Intensive Care Management
Patients progressing to the toxic phase require intensive care management including fluid resuscitation, electrolyte management, monitoring of kidney function and liver function, platelet and fresh frozen plasma transfusions if severe bleeding develops, and support for multi-organ failure. Some patients require dialysis for acute kidney injury.
Treatment Note
Because there is no specific antiviral treatment for yellow fever, recovery depends entirely on the patient’s immune system clearing the virus and surviving the complications that may develop. Early recognition of warning signs, close monitoring, and intensive supportive care are the only interventions available. Prevention through vaccination is therefore far more important than treatment.
Prevention
Yellow Fever Vaccination
The yellow fever vaccine (YFV) is a live attenuated vaccine that provides protection against yellow fever in approximately 95 percent of recipients. A single dose provides lifelong immunity in most recipients. Vaccination is the most effective prevention strategy and is recommended for anyone traveling to endemic areas including parts of West Africa. Ghana requires proof of yellow fever vaccination for travelers arriving from other endemic countries.
Use Insect Repellents
Apply DEET-based insect repellents to exposed skin, particularly during the early morning and late afternoon when Aedes mosquitoes are most active.
Wear Protective Clothing
Wearing long sleeves and long pants, particularly during peak mosquito activity times, reduces skin exposure and bite risk.
Use Insect Screens and Bed Nets
Install screens on windows and doors to keep mosquitoes out of homes. Sleeping under bed nets provides additional protection.
Eliminate Mosquito Breeding Sites
Removing standing water collections where Aedes mosquitoes breed reduces mosquito populations in local communities.
Prevention Note
Vaccination is the most important prevention strategy. Travelers to endemic areas should ensure vaccination at least 10 days before travel. The vaccine provides lifelong protection for most recipients, though booster doses are recommended by some guidelines if traveling again after many years.
Risk Factors
Travel and Geographic Risk Factors
These factors increase the risk of yellow fever exposure.
- Travel to or residence in endemic areas (parts of sub-Saharan Africa and South America)
- Travel to areas without adequate vaccination coverage
- Occupational exposure in healthcare or laboratory settings
- Travel during rainy season when mosquito populations are highest
Mosquito Exposure Risk Factors
These conditions increase the likelihood of mosquito bites.
- Living in or visiting urban areas where Aedes mosquitoes are present
- Outdoor exposure during early morning and late afternoon
- Inadequate use of insect repellents or protective clothing
- Unscreened housing
Individual Risk Factors
These personal factors increase the risk of severe yellow fever if infection occurs.
- Lack of yellow fever vaccination
- Pregnancy , pregnant women have documented higher rates of severe disease
- Age extremes (infants and older adults)
- Immunocompromised status
- Chronic medical conditions including diabetes and renal disease
- Previous dengue or other flavivirus infection , may increase risk of severe disease through antibody-dependent enhancement
Risk Note
Vaccination status is the single most important risk factor. Unvaccinated travelers to endemic areas have substantial risk of yellow fever. Vaccination status is therefore more important than any other individual or demographic factor.
Complications
Toxic Phase and Multi-Organ Failure
The toxic phase develops in approximately 15 percent of patients with symptomatic yellow fever and is characterized by a biphasic fever pattern with apparent recovery followed by recurrence of fever and signs of multi-organ failure. This phase has a case fatality rate of 50 to 85 percent even with intensive supportive care. Organs involved include the liver, kidneys, heart, and brain.
Hepatic Failure
The liver is a primary target organ for yellow fever virus. Hepatic failure develops during the toxic phase, presenting with jaundice, coagulopathy, elevated liver enzymes, and in severe cases, fulminant hepatic failure requiring intensive management.
Acute Kidney Injury
The kidneys are significantly affected by yellow fever virus, leading to acute kidney injury in severe cases. Oliguria or anuria may develop, requiring dialysis support. Some patients recover kidney function; others develop chronic renal impairment.
Hemorrhage and Coagulopathy
Yellow fever virus causes direct damage to blood vessel endothelium and produces coagulopathy through multiple mechanisms. Spontaneous bleeding, gastrointestinal hemorrhage, and other bleeding manifestations can develop during the toxic phase.
Encephalopathy
Encephalopathy (altered brain function) can develop during severe yellow fever, presenting with confusion, delirium, or altered consciousness.
Complication Note
The toxic phase represents the most severe manifestation of yellow fever and carries extremely high mortality. Early recognition of warning signs indicating progression from the febrile phase to the toxic phase is essential for mobilizing intensive care resources.
When to Seek Medical Care
Fever After Travel to Endemic Area
Any fever developing within three to six days after travel to a yellow fever endemic area, particularly in an unvaccinated person, should raise immediate suspicion for yellow fever. Seek medical evaluation promptly and inform your healthcare provider of your travel history and vaccination status.
Fever With Severe Backache
The combination of fever and severe lower back pain is relatively characteristic of yellow fever and should prompt evaluation specifically for this condition.
Biphasic Fever Pattern
If fever resolves after three to four days but then returns, or if initial improvement is followed by worsening symptoms, yellow fever should be considered and tested for.
Warning Signs of Toxic Phase
Seek urgent medical attention immediately if any of the following develop: jaundice, vomiting blood, black tarry stools, decreased urination, confusion, or spontaneous bleeding. These signs indicate progression to the toxic phase requiring intensive care.
Unvaccinated Travelers With Febrile Illness
Unvaccinated travelers who develop fever should be evaluated for yellow fever and other travel-related illnesses. If yellow fever is suspected, inform your healthcare provider immediately so that appropriate testing and isolation precautions can be implemented.
Emergency Advice
Because yellow fever can progress rapidly to severe, life-threatening disease, early medical evaluation is important. Do not wait for symptoms to worsen. If you have traveled to an endemic area and develop fever, seek medical attention promptly.
Prognosis
Approximately 85 Percent of Symptomatic Patients Recover
Most people who develop symptomatic yellow fever fever (approximately 85 percent) recover completely. These patients experience the febrile phase symptoms, which resolve, and they do not progress to the toxic phase. Recovery is gradual and complete.
Approximately 15 Percent Progress to Toxic Phase
Approximately 15 percent of symptomatic yellow fever cases progress to the toxic phase. The case fatality rate in the toxic phase is 50 to 85 percent even with intensive supportive care, making yellow fever one of the most dangerous febrile illnesses from a prognostic standpoint.
Long-Term Complications in Survivors of Severe Disease
Some patients who survive the toxic phase experience chronic complications including chronic kidney disease, neurological sequelae, and chronic fatigue.
Prognosis Note
The prognosis of yellow fever is determined primarily by whether the patient progresses to the toxic phase. Approximately 85 percent of symptomatic patients have good prognosis and recover fully. However, those who progress to the toxic phase face extremely poor prognosis. Prevention through vaccination is the only way to reliably prevent yellow fever. There is no effective treatment once infection has occurred.
Differential Diagnosis
Malaria
Both malaria and yellow fever present with fever, headache, and body aches, making early clinical distinction difficult. Key features: malaria typically develops gradually and recurrently; yellow fever typically has a biphasic pattern with apparent recovery and recurrence. Malaria causes a rash infrequently; yellow fever does not typically produce a rash. Backache is particularly characteristic of yellow fever but not malaria. Laboratory testing , rapid diagnostic test for malaria, serology or PCR for yellow fever , can distinguish them.
Dengue Fever
Dengue also presents with abrupt fever and severe muscle and joint pain. Dengue typically presents with more prominent joint pain than yellow fever. Dengue presents with a characteristic rash; yellow fever does not. Both are mosquito-borne viral illnesses, but yellow fever carries significantly higher risk of severe disease and death. Laboratory testing , NS1 antigen for dengue, serology for yellow fever , can distinguish them.
Typhoid Fever
Typhoid develops gradually with a step-ladder fever pattern; yellow fever typically has abrupt fever onset with biphasic pattern. Typhoid presents with constipation; yellow fever does not. Jaundice during the toxic phase of yellow fever distinguishes it from typhoid. Laboratory testing can distinguish them.
Leptospirosis
Leptospirosis also presents with abrupt fever, headache, and muscle pain. Both can present with biphasic fever patterns. Leptospirosis is associated with water exposure; yellow fever with travel to endemic areas or unvaccinated status. Laboratory testing can distinguish them.
Clinical Note
Travel history to endemic areas and vaccination status are key clinical clues that point toward yellow fever. The appearance of jaundice, particularly during apparent recovery from initial fever, strongly suggests progression to yellow fever’s toxic phase. Laboratory confirmation is essential because the consequences of missed yellow fever diagnosis , both for individual outcome and for public health surveillance , are significant.
References
World Health Organization (WHO) , Yellow Fever
World Health Organization comprehensive guidance on yellow fever epidemiology, transmission, diagnosis, treatment, and prevention. Updated February 2024.
Centers for Disease Control and Prevention (CDC) , Yellow Fever
CDC clinical guidance on yellow fever diagnosis, treatment, and management. Updated May 2024.
CDC Yellow Book 2024 , Yellow Fever
Comprehensive clinical reference for yellow fever including diagnostic criteria, clinical management, vaccination recommendations, and travel guidance. Updated April 2025.
Ghana Health Service , Disease Surveillance and Vaccination Programs
Ghana Health Service data on yellow fever epidemiology, vaccination requirements for travelers, and outbreak response protocols in Ghana.
StatPearls , Yellow Fever (NBK430701)
Evidence-based clinical overview of yellow fever covering pathophysiology, clinical presentation, diagnosis, and management. Updated April 2024.
Frequently Asked Questions
What is the difference between yellow fever and malaria if they both cause fever?
They share fever as a common symptom, but several features help distinguish them:
Yellow fever typically has a biphasic fever pattern , fever appears suddenly, improves after a few days, then returns. Malaria does not typically have this pattern. Yellow fever particularly causes severe backache; malaria does not. Yellow fever has no characteristic rash; dengue has a rash but yellow fever does not. Yellow fever causes jaundice (yellowing of skin and eyes) in severe cases; malaria does not.
Most importantly, yellow fever carries a much higher risk of severe disease and death than malaria. Yellow fever has a case fatality rate of 50 to 85 percent in severe cases, even with intensive care. Malaria treated appropriately typically recovers.
Laboratory testing , rapid diagnostic test for malaria, serology for yellow fever , can confirm which disease is present.
I am unvaccinated. How urgent is it to get the yellow fever vaccine before traveling to Ghana or West Africa?
It is very urgent. The yellow fever vaccine should be given at least 10 days before travel to endemic areas. The vaccine requires time for your immune system to develop protection , it does not provide immediate protection.
Vaccination status is the single most important factor determining your risk of yellow fever. Unvaccinated travelers to endemic areas have significant risk of infection. The vaccine provides lifelong protection in most recipients from a single dose.
If you plan to travel to Ghana or other West African countries, you should arrange vaccination at least 10 days before travel. In fact, Ghana officially requires proof of yellow fever vaccination for travelers arriving from other endemic countries. Without proof of vaccination, you may be vaccinated on arrival in Ghana.
If I had yellow fever once, am I protected from getting it again?
Yes. Yellow fever infection provides lifelong immunity. If you have had yellow fever, you have lifelong protection against that disease and cannot be infected again.
This is different from some other infections where reinfection is possible. Yellow fever immunity is lasting and permanent.
If I get yellow fever, is there any medicine that will cure it?
No. There is no specific antiviral medicine that kills the yellow fever virus. Once infected, treatment is entirely supportive , meaning your healthcare provider focuses on keeping you comfortable, managing fever and pain, maintaining hydration, and supporting your organs while your immune system fights off the infection.
Most people recover completely with supportive care alone. However, approximately 15 percent of patients progress to severe disease with multi-organ failure. Even intensive supportive care , which may include dialysis, blood transfusions, and mechanical ventilation , does not reliably prevent death in severe yellow fever.
This is why prevention through vaccination is so important. Vaccination prevents infection entirely, whereas treatment once infected has limited options.
Why should I get vaccinated if most people recover from yellow fever anyway?
Although most people (approximately 85 percent) do recover from yellow fever, approximately 15 percent progress to severe disease. Among those with severe disease, the case fatality rate is 50 to 85 percent even with the best available intensive care.
This means if you get yellow fever, you have approximately a 7.5 to 12.75 percent overall risk of dying, even if you receive intensive medical care. In some outbreak settings with limited medical resources, the case fatality rate is even higher.
Vaccination prevents yellow fever entirely. A single vaccine dose provides lifelong protection in approximately 95 percent of vaccinated individuals. The vaccine is far safer than the risk of yellow fever itself.
Additionally, vaccination protects not only you but also the broader community. Vaccinated individuals cannot spread yellow fever to others, reducing the risk for the entire population.